Recent studies have shown that the renal CYP450 (cytochrome P450) metabolites of AA (arachidonic acid), the vasoconstrictor 20-HETE (20-hydroxyeicosatetraenoic acid) and the vasodilator EETs (epoxyeicosatrienoic acids), play an important role in the pathophysiology of AngII (angiotensin II)-dependent forms of hypertension and the associated target organ damage. The present studies were performed in Ren-2 renin transgenic rats (TGR) to evaluate the effects of chronic selective inhibition of 20-HETE formation or elevation of the level of EETs, alone or in combination, on the course of hypertension and hypertension-associated end-organ damage. Both young (30 days of age) prehypertensive TGR and adult (190 days of age) TGR with established hypertension were examined. Normotensive HanSD (Hannover Sprague-Dawley) rats served as controls. The rats were treated with N-methylsulfonyl-12,12-dibromododec-11-enamide to inhibit 20-HETE formation and/or with N-cyclohexyl-N-dodecyl urea to inhibit soluble epoxide hydrolase and prevent degradation of EETs. Inhibition in TGR of 20-HETE formation combined with enhanced bioavailability of EETs attenuated the development of hypertension, cardiac hypertrophy, proteinuria, glomerular hypertrophy and sclerosis as well as renal tubulointerstitial injury. This was also associated with attenuation of the responsiveness of the systemic and renal vascular beds to AngII without modifying their responses to noradrenaline (norepinephrine). Our findings suggest that altered production and/or action of 20-HETE and EETs plays a permissive role in the development of hypertension and hypertension-associated end-organ damage in this model of AngII-dependent hypertension. This information provides a basis for a search for new therapeutic approaches for the treatment of hypertension.

Department of Nephrology 1st Medical Faculty Charles University Prague Czech Republic

Zobrazit více v PubMed

US Renal Data System: USRDS 2007. Chronic kidney disease. Am J Kidney Dis. 2008;51:S63–S80.

Bakris GL, Ritz E. The message for World Kidney Day 2009: hypertension and kidney disease: a marriage that should be prevented. J Clin Hypertens. 2009;11:144–147. PubMed PMC

Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251–287. PubMed

Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131–185. PubMed

Campbell WB, Falck JR. Arachidonic acid metabolites as endothelium-derived hyperpolarizing factors. Hypertension. 2007;49:590–596. PubMed

Capdevila JH, Falck JR, Imig JD. Role of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney Int. 2007;72:683–689. PubMed

Alonso-Galicia M, Maier KG, Greene AS, Cowley AW, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid in the renal and vasoconstrictor actions of angiotensin II. Am J Physiol. 2002;283:R60–R68. PubMed

Joly E, Seqqat R, Flamion B, Caron N, Michal A, Imig JD, Kramp R. Increased renal vascular reactivity to angiotensin II after unilateral nephrectomy in the rat involves 20-HETE. Am J Physiol. 2006;291:R977–R986. PubMed

Muthalif MM, Karzoun NA, Gaber L, Khandekar Z, Benter IF, Saeed AF, Parmentier JH, Estes A, Malik KU. Angiotensin II-induced hypertension: contribution of Ras GTPase/mitogen-activated protein kinase and cytochrome P-450 metabolites. Hypertension. 2000;36:604–609. PubMed

Kaergel E, Muller DN, Honeck H, Theuer J, Shagdarsuren E, Mullally A, Luft FC, Schunck WH. P450-dependent arachidonic acid metabolism and angiotensin II-induced renal damage. Hypertension. 2002;40:273–279. PubMed

Čertíková Chábová V, Kramer HJ, Vaněčková I, Vernerová Z, Eis V, Tesař V, Škaroupková P, Thumová M, Schejbalová S, Husková Z, Vaňourková Z, Kolský A, Imig JD, Červenka L. Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascular Pharmacol. 2007;47:145–159. PubMed

Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harboring the mouse Ren-2 gene. Nature. 1990;344:541–544. PubMed

Čertíková Chábová V, Kramer HJ, Vaněčková I, Thumová M, Škaroupková P, Tesař V, Falck JR, Imig JD, Červenka L. The roles of intrarenal 20-hydroxyeicosatetraenoic and epoxyeicosatrienoic acids in the regulation of renal function in hypertensive Ren-2 transgenic rats. Kidney Blood Press Res. 2007;30:335–346. PubMed

Wang MH, Brand-Schieber E, Zand BA, Nguyen X, Falck JR, Balu N, Schwartzman ML. Cytochrome P-450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors. J Pharmacol Exp Ther. 1998;284:966–973. PubMed

Morisseau C, Goodrow WH, Dowdy D, Zheng J, Greene JF, Sanborn JR, Hammock BD. Potent urea and carbamate inhibitors of soluble epoxide hydrolase. Proc Nat Acad Sci. 1999;96:8849–8854. PubMed PMC

Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39:690–694. PubMed

Vaněčková I, Kramer HJ, Bäcker A, Schejbalová S, Vernerová Z, Eis V, Opočenský M, Dvořák P, Červenka L. Early-onset endothelin receptor blockade in hypertensive heterozygous Ren-2 rats. Vascular Pharmacol. 2006;45:163–170. PubMed

Opočenský M, Kramer HJ, Bäcker A, Vernerová Z, Eis V, Červenka L, Vaněčková I. Late-onset endothelin-A receptor blockade substantially improves survival rate in homozygous hypertensive Ren-2 rats. Hypertension. 2006;48:965–971. PubMed

Husková Z, Kramer HJ, Vaňourková Z, Červenka L. Effects of changes in sodium balance on plasma and kidney angiotensin II levels in anesthetized and conscious Ren-2 transgenic rats. J Hypertens. 2006;24:517–527. PubMed

Husková Z, Kramer HJ, Thumová M, Vaňurková Z, Bürgelová M, Teplan V, Malý J, Červenka L. Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press Res. 2006;29:74–83. PubMed

Vaňourková Z, Kramer HJ, Husková Z, Vaněčková I, Opočenský M, Čertíková Chábová V, Tesař V, Škaroupková P, Thumová M, Dohnalová M, Mullins JJ, Červenka L. AT1 receptor blockade is superior to conventional triple therapy in protecting against end-organ damage in Cyp1a1-Ren-2 transgenic rats with inducible hypertension. J Hypertens. 2006;24:2465–2472. PubMed

Sandberg MC, Laborde C. Glomerulosclerosis and tubulointerstitial fibrosis are attenuated with 17-beta-estradiol in the aging Dahl salt sensitive rat. J Am Soc Nephrol. 2004;15:1546–1556. PubMed

Nakano Y, Hirano T, Uehara K, Nishibayashi S, Hattori K, Aihara M, Yamada Y. New rat model induced by anti-glomerular basement membrane antibody shows sever glomerular adhesion in early stage and quickly progresses to end-stage renal failure. Pathol Int. 2008;58:361–370. PubMed

Weibel ER. Practical Methods for Biological Morphometry. London: Academic Press; 1979. Stereological Methods; pp. 44–46.

Lane PH, Steffes MW, Mauer MS. Estimation of glomerular volume: a comparison of four methods. Kidney Int. 1992;41:1085–1089. PubMed

Jacinto SM, Mullins JJ, Mitchell KD. Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats. Am J Physiol. 1999;276:F315–F322. PubMed

Kopkan L, Kramer HJ, Husková Z, Vaňourková Z, Škaroupková P, Thumová M, Červenka L. The role of intrarenal angiotensin II in the development of hypertension in Ren-2 transgenic rats. J Hypertens. 2005;23:1531–1539. PubMed

Lee MA, Böhm M, Paul M, Bader M, Ganten U, Ganten D. Physiological characterization of the hypertensive transgenic rat TGR(mRen2)27. Am J Physiol. 1996;270:E919–E929. PubMed

Mitchell KD, Jacinto SM, Mullins JJ. Proximal tubular fluid, kidney, and plasma levels of angiotensin II in hypertensive Ren-2 transgenic rats. Am J Physiol. 1997;273:F246–F253. PubMed

Sarkis A, Lopez B, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Opin Nephrol Hypertens. 2004;13:205–214. PubMed

Zhao X, Pollock DM, Zeldin DC, Imig JD. Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension. 2003;42:775–780. PubMed

Jung O, Brandes RP, Kim I-H, Schweda F, Schmidt R, Hammock BD, Busse R, Fleming I. Soluble epoxide hypdrolase is a main effector of angiotensin II-induced hypertension. Hypertension. 2005;45:759–765. PubMed

Zou AP, Fleming JT, Falck JR, Jacobs ER, Gebremedhin D, Harder DR, Roman RJ. 20-HETE is an endogenous inhibitor of the large-conductance Ca2+-activated K+ channel in renal arterioles. Am J Physiol. 1996;270:R228–R237. PubMed

Gebremedhin D, Lange AR, Narayanan J, Aebly MR, Jacobs ER, Harder DR. Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2+ current. J Physiol. 1998;507:771–781. PubMed PMC

Randriamboavonjy V, Busse R, Fleming I. 20-HETE-induced contraction of small coronary arteries depends on the activation of Rho-Kinase. Hypertension. 2003;41:801–806. PubMed

Imig JD, Pham BT, LeBlanc EA, Reddy KM, Falck JR, Inscho EW. Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses. Hypertension. 2000;35:307–312. PubMed

Oyekan AO, McGiff JC. Cytochrome P-450-derived eicosanoids participates in the renal functional effects of ET-1 in the anaesthetized rat. Am J Physiol. 1998;274:R52–R61. PubMed

Singh H, Schwartzman ML. Renal vascular cytochrome P450-derived eicosanoids in androgen-induced hypertension. Pharmacol Rep. 2008;60:29–37. PubMed

Quigley R, Baum M, Reddy KM, Griener JC, Falck JR. Effects of 20-HETE and 19(S)-HETE on rabbit proximal straight tubule volume transport. Am J Physiol. 2000;278:F949–F953. PubMed PMC

Yu M, Lopez B, Dos Santos EA, Falck JR, Roman RJ. Effects of 20-HETE on Na+-K+-ATPase activity in the thick ascending loop of Henle. Am J Physiol. 2007;292:R2400–R2405. PubMed

Hoagland KM, Flasch AK, Roman RJ. Inhibitors of 20-HETE formation promote salt-sensitive hypertension in rats. Hypertension. 2003;42:669–673. PubMed

Imig JD, Zhao X, Falck JR, Wei S, Capdevila JH. Enhanced renal mircovascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. J Hypertens. 2001;19:983–992. PubMed

Imig JD, Falck JR, Wei S, Capdevila JH. Epoxygenase metabolites contribute to nitric oxide-independent afferent arteriolar vasodilatation in response to bradykinin. J Vasc Res. 2001;38:247–255. PubMed

Wang D, Borrego-Conde LJ, Falck JR, Sharma KK, Wilcox CS, Umans JG. Contribution of nitric oxide, EDHF, and EETs to endothelium-dependent relaxation in renal afferent arterioles. Kidney Int. 2003;63:2187–2193. PubMed

Kohagure K, Endo Y, Ito O, Arima S, Omata K, Ito S. Endogenous nitric oxide and epoxyeicosatrienoic acids modulate angiotensin II-induced constriction in the rabbit afferent arteriole. Acta Physiol Scand. 2000;168:107–112. PubMed

Madhun ZT, Goldthwait DA, McKay D, Hopfer U, Douglas JG. An epoxygenase metabolite of arachidonic acid mediates angiotensin II-induced rises in cytosolic calcium in rabbit proximal tubule epithelial cells. J Clin Invest. 1991;88:456–461. PubMed PMC

Sakairi Y, Jacobson HR, Noland DT, Capdevila JH, Falck JR, Breyer MD. 5,6-EET inhibits ion transport in collecting duct by stimulating endogenous prostaglandin synthesis. Am J Physiol. 1995;268:F931–F939. PubMed

Imig JD. Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. Am J Physiol. 2005;289:F496–F503. PubMed

Yoshida Y, Kawamura T, Ikoma M, Fogo A, Ichikawa I. Effects of antihypertensive drugs on glomerular morphology. Kidney Int. 1989;36:626–635. PubMed

Dworkin LD, Feiner HD, Parker M, Tolbert E. Effects of nifedipine and enalapril on glomerular structure and function in uninephrectomized SHR. Kidney Int. 1991;39:1112–1117. PubMed

Imig JD, Hammock BD. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat Rev Drug Discov. 2009;8:794–805. PubMed PMC

McGiff JC. Cytochrome P-450 metabolism of arachidonic acid. Ann Rev Pharmacol Toxicol. 1991;31:339–169. PubMed

Makita K, Falck JR, Capdevila JH. Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for old enzyme system. FASEB. 1996;10:1456–1463. PubMed

Sakuma S, Usa K, Fujimoto Y. 15-hydroperoxyeicosapentaenoic acid, but not eicosapentaenoic acid, shifts arachidonic acid away from cyclooxygenase pathway into acyl-CoA synthetase pathway in rabbit kidney medulla microsomes. ProstaglandinsLeukot Essent Fatty Acids. 2006;75:69–74. PubMed

Spector AA. Arachidonic acid cytochrome P450 epoxygenase pathway. J Lipid Res. 2009;50:S52–S60. PubMed PMC

Zicha J, Kuneš J. Ontogenetic aspects of hypertension development: analysis in the rat. Physiol Rev. 1999;79:1227–1282. PubMed

Muthalif MM, Benter LF, Karzoun N, Fatima S, Harper J, Uddin MR, Malik KU. 20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. Proc Natl Acad Sci USA. 1998;95:12701–12706. PubMed PMC

Parmentier J-H, Muthalif MM, Nishimoto AT, Malik KU. 20-Hydroxyeicosatetraenoic acid mediates angiotensin II-induced phospholipase D activation in vascular smooth muscle cells. Hypertension. 2001;37:623–629. PubMed

Yaghini FA, Zhang C, Parmentier JH, Estes AM, Jafari N, Schaefer SA, Malik KU. Contribution of arachidonic acid metabolites derived via cytochrome P4504A to angiotensin II-induced neointimal growth. Hypertension. 2005;45:1182–1187. PubMed

Camara NO, Martins JO, Landgraf RG, Jancar S. Emerging roles for eicosanoids in renal diseases. Curr Opin Nephrol Hypertens. 2009;18:21–27. PubMed

Research on Experimental Hypertension in Prague (1966-2009)

Effects of Renal Denervation on the Enhanced Renal Vascular Responsiveness to Angiotensin II in High-Output Heart Failure: Angiotensin II Receptor Binding Assessment and Functional Studies in Ren-2 Transgenic Hypertensive Rats

20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats

Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Ren-2 transgenic hypertensive rats

Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME

Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension

Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats